Email updates

Keep up to date with the latest news and content from JTM and BioMed Central.

Open Access Research

A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols

Sebastian Attig1, Leah Price2, Sylvia Janetzki3, Michael Kalos4, Michael Pride5, Lisa McNeil5, Tim Clay6, Jianda Yuan7, Kunle Odunsi8, Axel Hoos9, Pedro Romero10, Cedrik M Britten111* and the CRI-CIC Assay Working Group

Author Affiliations

1 Division of Translational and Experimental Oncology, Department of Internal Medicine III, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany

2 Department of Biostatistics, New York University, New York, NY USA

3 ZellNet Consulting, Inc., Fort Lee, NJ USA

4 Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Abramson Family Cancer Research Institute, Philadelphia, PA USA

5 Vaccine Research East and Early Development, Pfizer Inc. Pearl River, NY USA

6 Surgery and Immunology, Duke University Medical Center, Durham, NC, USA

7 Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, NY USA

8 Departments of Gynecologic Oncology and Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA

9 Bristol-Myers Squibb, Wallingford, CT USA

10 Translational Tumor Immunology Group, Ludwig Center for Cancer Research of the University of Lausanne, Switzerland

11 Research & Development, BioNTech AG, Mainz, Germany

For all author emails, please log on.

Journal of Translational Medicine 2011, 9:108  doi:10.1186/1479-5876-9-108

Published: 11 July 2011

Additional files

Additional file 1:

Figure S1 and Tables S1 and S2

Format: PPT Size: 2.3MB Download file

This file can be viewed with: Microsoft PowerPoint Viewer

Open Data